A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Neoadjuvant Carboplatin and Paclitaxel, With or Without Debio 1143 in Patients With Newly Diagnosed Advanced Epithelial Ovarian Cancer

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Neoadjuvant Carboplatin and Paclitaxel, With or Without Debio 1143 in Patients With Newly Diagnosed Advanced Epithelial Ovarian Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs AT 406 (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary) ; Antineoplastics
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors Debiopharm
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top